[Frontiers in Bioscience E2, 1099-1104, June 1, 2010]

Biomarkers in lung cancer

Alessandra Bearz1, Massimiliano Berretta1, Alessandro Cappellani2, Arben Lleshi1, Eleonora Berto, Lucia Fratino1, Umberto Tirelli1

1Department of Medical Oncology, CRO-IRCCS, Aviano (PN), Italy, 2Department of Surgery, University of Catania, Italy


1. Abstract
2. Introduction
2. Introduction
3. Circulating markers
3.1. Small cell lung cancer
3.1.1. Neuron-specific enolase
3.1.2. Chromogranin A (CgA)
3.2. Non small cell lung cancer
3.2.1. Cyfra 21-1
3.2.2. Ca 15-3
3.2.3. Carcinoembryonic Antigen
3.2.4. Ca 19-9
3.2.5. Squamous cell carcinoma
4. Tissutal markers
4.1. Excision repair cross-complementing-1
4.2. RRM1
4.3. BRAC1
4.4. Epidermal growth factor receptor
4.5. k-RAS
4.6. Calcitonin
5. Acknowledgments
6. References


Here we review the role of tissutal and circulating biomarkers in the management of lung cancer. In the past they were considerate quite ineffective tools as regards prognosis and prediction of treatment activity, nowadays instead, they are becoming a crucial key point as potential predictive issues in driving therapy, with possibly prognostic values as well.